Hikma Pharmaceuticals (LON:HIK) Stock Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Hikma Pharmaceuticals PLC (LON:HIK) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of GBX 1,921.37 ($24.95) and traded as high as GBX 2,022 ($26.25). Hikma Pharmaceuticals shares last traded at GBX 1,997 ($25.93), with a volume of 189,613 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Berenberg Bank upgraded Hikma Pharmaceuticals to a “buy” rating and upped their price target for the stock from GBX 2,100 ($27.27) to GBX 2,400 ($31.16) in a research note on Monday, September 2nd.

Hikma Pharmaceuticals Stock Down 0.1 %

The stock has a market cap of £4.43 billion, a price-to-earnings ratio of 3,072.31, a PEG ratio of 2.38 and a beta of 0.41. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.48. The business’s fifty day moving average is GBX 1,955.53 and its two-hundred day moving average is GBX 1,921.37.

Hikma Pharmaceuticals Cuts Dividend

The business also recently disclosed a dividend, which was paid on Friday, September 20th. Stockholders of record on Thursday, August 15th were given a dividend of $0.32 per share. This represents a dividend yield of 1.37%. The ex-dividend date was Thursday, August 15th. Hikma Pharmaceuticals’s dividend payout ratio is currently 9,538.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.